Skip to main content

Table 3 Prostatectomy patient characteristics and outcomes for men ≤55 years compared to men >55 years

From: Men under the age of 55 years with screen detected prostate cancer do not have less significant disease compared to older men in a population of patients in Australia

Characteristic

Age ≤55 years

Age >55 years

Total

Significance

Sample numbers

110 (15.2 %)

613 (84.8 %)

723 (100 %)

X2 = 349.9, p < 0.001

Age (years)

    

 -Median

53

64

63

 

 -Range

41–55

56–79

41–79

 -Mean

52.0

64.2

62.4

PSA score (ng/mL)

    

 <3

11 (10.0 %)

67 (10.9 %)

78 (10.8 %)

X2 = 0.08, p = 0.77

 3–4

25 (22.7 %)

43 (7.0 %)

68 (9.4 %)

X2 = 27.02, p < 0.001

 4.1–10

62 (56.4 %)

402 (65.6 %)

464 (64.2 %)

X2 = 3.45, p = 0.06

 10.1–20

7 (6.4 %)

90 (14.7 %)

94 (13.4 %)

X2 = 5.56, p = 0.02

 >20.1

4 (3.6 %)

8 (1.3 %)

12 (1.7 %)

X2 = 3.11, p = 0.08

 Missing

1 (0.9 %)

3 (0.5 %)

4 (0.6 %)

X2 = 0.30, p = 0.59

 Continuous variable

110

613

723

(t = −0.365, p = 0.72, mean difference = −0.29, 95 % CI of difference = −1.86 to 1.28)

Gleason score

    

 3 + 3

26 (23.6 %)

96 (15.7 %)

122 (16.9 %)

X2 = 4.23, p = 0.40

 3 + 4

57 (51.8 %)

326 (53.2 %)

383 (53.0 %)

X2 = 0.70, p = 0.79

 4 + 3

19 (17.3 %)

128 (20.9 %)

147 (20.3 %)

X2 = 0.75, p = 0.39

 8

3 (2.7 %)

13 (2.1 %)

16 (2.2 %)

X2 = 0.16, p = 0.69

 9–10

5 (4.5 %)

50 (8.2 %)

55 (7.6 %)

X2 = 1.73, p = 0.19

 >6

84 (76.4 %)

517 (84.3 %)

601 (83.1 %)

X2 = 4.23, p = 0.40

 >7

8 (7.3 %)

63 (10.3 %)

71 (9.8 %)

X2 = 0.95, p = 0.33

 Continuous variable

mean = 2.13

mean = 2.34

t = −2.00

Std dev = 0.96

Std dev = 1.04

p = 0.05

Mean difference = −0.212

95 % CI of difference = −0.42 to 0.00

Pathological stage

    

 pT2

72 (65.5 %)

365 (59.5 %)

437 (60.4 %)

X2 = 1.36, p = 0.24

 pT3a

24 (21.8 %)

167 (27.2 %)

191 (26.4 %)

X2 = 1.41, p = 0.24

 pT3b

14 (12.7 %)

80 (13.1 %)

94 (13.0 %)

X2 = 0.01, p = 0.93

 pT4

0 (0 %)

0 (0 %)

0 (0 %)

-

 Missing

0 (0 %)

1 (0.2 %)

1 (0.1 %)

X2 = 0.18, p = 0.67

Prostate weight

Mean = 46.40

Mean = 54.83

 

t = −5.11,

Std dev = 14.86

Std dev = 20.72

df = 191.8,

p < 0.001,

95 % CI = −11.69 to −5.17

Tumour volume

    

 <0.5

21 (19.1 %)

109 (17.8 %)

130 (18.0 %)

X2 = 0.11, p = 0.74

 0.5-1

23 (20.9 %)

107 (17.5 %)

130 (18.0 %)

X2 = 0.75, p = 0.39

 1.1-2

17 (15.5 %)

106 (17.3 %)

123 (17.0 %)

X2 = 0.22, p = 0.64

 2.1+

13 (11.8 %)

123 (20.1 %)

136 (18.8 %)

X2 = 4.15, p = 0.04

 Missing

36 (32.7 %)

168 (27.4 %)

204 (28.2 %)

X2 = 1.30, p = 0.25

 Mean tumour volume

Mean = 1.37

Mean = 1.82

 

t = −1.628,

Std dev = 1.51

Std dev = 2.34

df = 516,

p = 0.104,

95 % CI = −1.01 to 0.95

Seminal vesicle

    

 Negative

102 (92.7 %)

566 (92.3 %)

668 (92.4 %)

X2 = 0.02, p = 0.89

 Positive

8 (7.3 %)

47 (7.7 %)

55 (7.6 %)

Lymph nodes

    

 Negative

69 (62.7 %)

384 (62.6 %)

453 (62.7 %)

X2 = 0.00, p = 0.99

 Positive

4 (3.6 %)

16 (2.2 %)

20 (2.8 %)

X2 = 0.37, p = 0.55

 Not taken

37 (33.6 %)

213 (29.5 %)

250 (34.6 %)

X2 = 0.05, p = 0.82

Insignificant prostate cancer (Stamey criteria)

10 (9.1 %)

40 (6.5 %)

50 (6.9 %)

X2 = 1.25, p = 0.26

Missing

10 (9.1 %)

29 (4.7 %)

39 (5.4 %)

Total

110

613

723

Clinical stage

    

 -Organ confined (pT2, N0NX)

72 (65.5 %)

363 (59.3 %)

435 (60.2 %)

X2 = 1.47, p = 0.23

 -Non-Organ confined (pT3/4, N0-1)

38 (34.5 %)

249 (40.7 %)

287 (39.8 %)

Margin positive

27 (24.5 %)

156 (25.4 %)

183 (25.3 %)

X2 = 0.40, p = 0.84

High risk PCa

    

 GS > 7

8 (7.3 %)

63 (10.3 %)

71 (9.8 %)

X2 = 0.95, p = 0.33

 PSA > 20

4 (3.6 %)

8 (1.3 %)

12 (1.7 %)

X2 = 3.11, p = 0.08

 Clinical stage > T2b

15 (13.6 %)

89 (14.5 %)

104 (14.4 %)

X2 = 0.06, p = 0.81

 At least one feature of high risk PCa

22 (20.0 %)

147 (24.0 %)

169 (23.4 %)

X2 = 0.83, p = 0.36